Laura Waters
0000-0002-1379-1775
Publication & Citation Trends
Publications
0 total
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Cited by 14
Semantic Scholar
Abstract 3786: Combination of MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors for the treatment of MTAP-deleted KRAS-mutant pancreatic cancer
Cited by 1
Semantic Scholar
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.
Cited by 4
Semantic Scholar
Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC
Cited by 1
Semantic Scholar
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein OA
Cited by 11
Semantic Scholar
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading OA
Cited by 21
Semantic Scholar
Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers
Cited by 3
Semantic Scholar
Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers
Cited by 1
Semantic Scholar
Research Topics
HIV/AIDS drug development and treatment
(85)
HIV/AIDS Research and Interventions
(78)
HIV Research and Treatment
(54)
HIV-related health complications and treatments
(44)
HIV, Drug Use, Sexual Risk
(21)
Affiliations
National Health Service
University College Hospital
National Institutes of Health
University College London Hospitals NHS Foundation Trust
Janssen (Belgium)